URGN today
$26.10+$0.78 (+3.08%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourLeaning Bullish
15 minSymmetric Triangle
5 minBullish
Daily trend turns up above $36.46
Key levels
Resistance$32.39
Resistance$30.00
Support$26.00
Support$22.61
Latest news & SEC filings
AnalystGuggenheim keeps Buy rating on UroGen Pharma but cuts price target
AnalystGuggenheim keeps Buy rating on UroGen Pharma, cuts price target to $56
EarningsUroGen Pharma holds Q3 2026 earnings call
EarningsUroGen Pharma Posts Financials for Q3 of 2026
All URGN news →About UroGen Pharma
UroGen Pharma is a biotechnology company that develops treatments for cancers of the urinary tract and other specialty cancers. Its approved products, Jelmyto and Zusduri, use the company's RTGel hydrogel technology to deliver mitomycin for a type of upper urinary tract cancer and for a form of bladder cancer that returns after treatment. The company also has an immuno-uro-oncology pipeline, including UGN-501, an investigational oncolytic virus. UroGen Pharma operates primarily in the United States, with research and development activities in Israel.
Based on the company's 10-K filed Mar 2, 2026.
Nasdaq · Healthcare
UroGen Pharma Ltd. (URGN)
What Is the Price Target for URGN?
SEPT Low Target
$42.00
SEPT Mid Target
$59.00
SEPT High Target
$75.00
Analyst Consensus
$59.00
Is URGN a Buy or Sell Right Now?
Thesis
- •Revenue growing 21.4% YoY with STRONG trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment rising.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for URGN.
Start Free Trial →Is URGN Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$59.00
48
Moat Score
NARROW
1/9
Piotroski Score
-4.1
Altman Z-Score
What Is Smart Money Doing with URGN?
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Degnan Chris | officer | Buy | 4,483 | - | Oct 8, 2026 |
| Degnan Chris | officer | Sale | 2,202 | $81K | Oct 8, 2026 |
| Robinson James A. Jr. | director | Buy | 2,000 | - | Aug 26, 2026 |
| Schoenberg Mark | officer | Sale | 5,222 | $143K | Jun 8, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →URGN Growth Story
Revenue YoY
21.4%
3yr Revenue CAGR
19.5%
EPS Growth YoY
N/A
FCF Growth YoY
-85.3%
Revenue Trend
STRONG
Dark Pool Trades for URGN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for URGN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:25:52 | $26.10 | 6,944 | $$181K | SELL |
| 21:38:45 | $26.10 | 65,852 | $$1.7M | SELL |
| 21:00:29 | $26.10 | 1,513 | $$39K | BUY |
| 21:00:02 | $26.10 | 3,400 | $$89K | SELL |
| 21:00:02 | $26.10 | 2,208 | $$58K | BUY |
5 dark pool trades shown · $$2.1M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for URGN
PREVIEWSEPT Investing provides real-time options flow tracking for URGN, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $27 | Nov 20 | 9 | $$700 | 5 | SWEEP |
| CALL | $27 | Nov 20 | 9 | $$700 | 5 | SWEEP |
| CALL | $27 | Nov 20 | 9 | $$840 | 6 | SWEEP |
| CALL | $27 | Nov 20 | 9 | $$840 | 6 | SWEEP |
| CALL | $27 | Nov 20 | 9 | $$700 | 5 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for UroGen Pharma Ltd. (URGN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →URGN — frequently asked questions
What is URGN stock price today?
UroGen Pharma Ltd. (URGN) is at $26.10, up 3.08% (+$0.78) at the Nov 11, 2026 close.
Why is URGN stock moving today?
Latest URGN news — Nov 6, 2026: Guggenheim keeps Buy rating on UroGen Pharma but cuts price target · Nov 5, 2026: Guggenheim keeps Buy rating on UroGen Pharma, cuts price target to $56
What is the URGN price target?
The average analyst price target for URGN is $59.00, ranging from $42 to $75, based on 6 analysts.
What do analysts rate URGN?
Analyst ratings for URGN: 0 Buy, 11 Hold, 0 Sell — consensus Hold.
Did URGN beat earnings?
URGN last reported on Aug 5, 2026: EPS -$0.28 vs -$0.27 expected — a miss of 5.7%.
Does URGN pay a dividend?
URGN does not currently pay a dividend.
How much debt does URGN have?
UroGen Pharma Ltd. reported $200M of debt and $79M of cash (Jun 30, 2026).
What are URGN support and resistance levels?
Support: $26.00, $22.61, $17.75. Resistance: $30.00, $32.39, $34.97.
What are insiders doing with URGN?
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.
What is the latest news on URGN?
Nov 6, 2026: Guggenheim keeps Buy rating on UroGen Pharma but cuts price target · Nov 5, 2026: Guggenheim keeps Buy rating on UroGen Pharma, cuts price target to $56 · Nov 4, 2026: UroGen Pharma holds Q3 2026 earnings call